Beacon Therapeutics Secures $33 Million in Series A Funding for Vision-Restoring Ophthalmic Gene Therapy

In a significant leap forward for vision restoration, Beacon Therapeutics has successfully raised $33 million to advance its pioneering work in ophthalmic gene therapy. Founded in 2023, Beacon Therapeutics is dedicated to saving and restoring the sight of patients suffering from various retinal diseases that often lead to blindness. The funding will principally support the company’s lead candidate, AGTC-501, which is currently in Phase II clinical trials targeting X-linked retinitis pigmentosa (XLRP)—a rare inherited disorder marked by progressive vision loss primarily affecting boys and young men due to mutations in the RPGR gene. Beacon Therapeutics aims to tackle the complexities of XLRP head-on by utilizing AGTC-501, which expresses the full-length RPGR protein to mitigate the extensive damage to both rod and cone photoreceptors. In addition to this advanced program, the funding will enable the company to further develop two preclinical programs targeting other pressing issues in ophthalmology—the dry form of age-related macular degeneration (AMD) and cone-rod dystrophy (CRD). Backed by a robust group of investors including Syncona, Forbion, Oxford Science Enterprises, TCGX, and Advent Life Sciences, Beacon Therapeutics is well-positioned to leverage its innovative target generation technology platform designed to discover and screen secreted proteins crucial for eye health. This substantial investment represents a pivotal moment for Beacon Therapeutics as it continues to push the boundaries of what's possible in gene therapy for retinal diseases, offering renewed hope to countless patients facing vision loss.